Soligenix (SNGX) Net Margin (2010 - 2024)
Soligenix's (SNGX) quarterly Net Margin came in at 70217.85% in Q2 2024, down 6943883.0% YoY from N/an in Q3 2023, and down 4190.4% on a QoQ basis from 1636.63% in Q1 2024.
Soligenix (SNGX) Net Margin (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of Net Margin data on file, last reported at 70217.85% in Q2 2024.
- Quarterly Net Margin fell 6943883.0% year-over-year to 70217.85% in Q2 2024, while the trailing twelve-month figure through Dec 2024 was 6925.11% (down 619351.0% YoY) and the FY2024 annual result came in at 6925.11%, down 619351.0% from the prior year.
- Net Margin retreated to 70217.85% in Q2 2024, from 1636.63% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 294.04% in Q3 2020 to a low of 70217.85% in Q2 2024.
- A 5-year average of 4999.31% and a median of 1034.63% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin surged 190577 bps — and 2024, when it plunged 6943883 bps.
- Tracing SNGX's Net Margin over 5 years: stood at 775.26% in 2020, then tumbled by 120 bps to 1706.45% in 2021, then jumped by 40 bps to 1025.37% in 2022, then advanced by 28 bps to 743.38% in 2023, then tumbled by 9346 bps to 70217.85% in 2024.
- The last three Net Margin figures came in at 70217.85% (Q2 2024), 1636.63% (Q1 2024), and 743.38% (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 12.09% |
| 10 | Soligenix | 6.15 Mn | 6.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -70,217.85% |
| Mar 31, 2024 | -1,636.63% |
| Dec 31, 2023 | -743.38% |
| Sep 30, 2023 | -1,274.69% |
| Jun 30, 2023 | -779.02% |
| Mar 31, 2023 | -406.76% |
| Dec 31, 2022 | -1,025.37% |
| Sep 30, 2022 | -1,991.70% |
| Jun 30, 2022 | -1,043.89% |
| Mar 31, 2022 | -2,312.53% |
| Dec 31, 2021 | -1,706.45% |
| Sep 30, 2021 | -1,926.74% |
| Jun 30, 2021 | -883.08% |
| Mar 31, 2021 | -1,600.67% |
| Dec 31, 2020 | -775.26% |
| Sep 30, 2020 | -294.04% |
| Jun 30, 2020 | -549.54% |
| Mar 31, 2020 | -820.00% |
| Dec 31, 2019 | -144.85% |
| Sep 30, 2019 | -287.31% |